iCardiac Technologies, Inc. and Pfizer have into a multiyear research alliance to develop and validate advanced ECG-based cardiac safety biomarkers utilizing the COMPAS technology platform.
The COMPAS technology was developed at the University of Rochester within its Heart Research Follow-Up Program (HRFUP), a premier group of electrocardiology researchers focused on the ventricular repolarization process of the heart, and exclusively licensed to iCardiac.
The alliance is aimed further development of iCardiac's COMPAS platform and advanced ECG markers for use in the safety testing of in-development and on-market drugs, and includes a cross-licensing arrangement by which iCardiac will receive rights to ECG analysis technologies developed within Pfizer.
According to a release from iCardiac Technologies, the companies will collaborate on a research program comprised of a series of studies, including retrospective and prospective ECG data analyses. iCardiac will receive an equity investment and technology license payment, plus research and development funding over the term of the alliance. iCardiac will retain commercial rights to the validated technology platform and new biomarkers for future application in cardiac safety clinical trials and technologies.
For further information visit www.icardia.com.
July 10, 2024 
